" class="no-js "lang="en-US"> Martial Marcotti - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Martial Marcotti

Martial Marcotti

About Martial Marcotti

Martial has 10 years’ experience in software project management. After 6 years working at Cognizant on projects for large international groups, he joined Kayentis in 2018. At Kayentis, he worked on clinical projects before moving to product and services management. He was appointed Strategic Marketing Director in October 2021.

Related Story

Clinical Trials

 Kayentis Launches Fully Integrated Platform for Decentralized Clinical Trials | Pharmtech Focus|Kayentis Launches Fully Integrated Platform for Decentralized Clinical Trials | Pharmtech Focus

Kayentis Launches Fully Integrated Platform for Decentralized Clinical Trials

March 23 2022

Kayentis, a global provider of eCOA and Decentralized Clinical Trial solutions, today announces the launch […]